Medication info
Glucodown Tablet 250 Milligrams (Metformin Hydrochloride)

Glucodown Tablet 250 Milligrams (Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›250mg / 1 tablet
Manufacturer / importer
Hanol Bio Pharma Co., Ltd.
Appearance
White round film-coated tablets
Packaging
500 tablets/bottle
Approval status
Active

MFDS item code 201604290 · Approved 2016.07.12 · Insurance code 655604850

Summary

Main use
Treatment of type 2 diabetes mellitus
Who uses it
Adults · Children
Adult dosage
The dose should be determined individually based on efficacy and tolerability and should not exceed the recommended maximum daily dose. To reduce gastrointestinal adverse reactions and identify the minimum dose required for adequate glycemic control, treatment must be initiated at a low dose: 500mg per dose, 2~3 times daily, with meals. Increase the dose gradually by 500mg each week. When the dose is up to 2000mg, it is usually divided into 2 doses per day, taken in the morning and evening. For doses exceeding 2000mg, divide the dose into 3 doses per day and take with meals; the maximum daily dose is 2550mg. At initiation of treatment and during dose adjustments, measure fasting blood glucose to assess the response to this medicine and determine the minimum effective dose. Measure the blood glycosylated hemoglobin concentration at approximately 3-month intervals. The treatment goal with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycosylated hemoglobin concentrations to normal or near-normal levels using the minimum effective dose. In patients whose blood glucose is generally controlled by diet alone but becomes temporarily uncontrolled, short-term treatment with this medicine may be sufficient to achieve an adequate effect. This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 850mg once daily. The maximum daily dose is 1000mg, divided into 2 doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73㎡, respectively, this medicine must be discontinued immediately.
Children's dosage
Children aged 10 years and older or adolescents who are growing: The usual starting dose is 500 milligrams once daily, taken during or after a meal. Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse effects may improve with gradual dose increases. The maximum daily dose is 2000mg. Divide this dose into 2~3 doses.

Ingredients

Manufacturer
Hanol Bio Pharma Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus

  • Type 2 diabetes
View approved original text

This medication is used in patients with type 2 diabetes whose blood sugar is not sufficiently controlled by diet and exercise alone, particularly in overweight adults and children aged 10 years and older. In adults, it may be used alone or in combination with other oral hypoglycemic agents or insulin. It helps in blood sugar control both in children and adolescents when used as monotherapy or in combination with insulin. This medication effectively controls blood sugar and plays an important role in diabetes management.

Dosage and Administration

Adult dosage

The dose should be determined individually based on efficacy and tolerability and should not exceed the recommended maximum daily dose. To reduce gastrointestinal adverse reactions and identify the minimum dose required for adequate glycemic control, treatment must be initiated at a low dose: 500mg per dose, 2~3 times daily, with meals. Increase the dose gradually by 500mg each week. When the dose is up to 2000mg, it is usually divided into 2 doses per day, taken in the morning and evening. For doses exceeding 2000mg, divide the dose into 3 doses per day and take with meals; the maximum daily dose is 2550mg. At initiation of treatment and during dose adjustments, measure fasting blood glucose to assess the response to this medicine and determine the minimum effective dose. Measure the blood glycosylated hemoglobin concentration at approximately 3-month intervals. The treatment goal with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycosylated hemoglobin concentrations to normal or near-normal levels using the minimum effective dose. In patients whose blood glucose is generally controlled by diet alone but becomes temporarily uncontrolled, short-term treatment with this medicine may be sufficient to achieve an adequate effect. This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who have no other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 850mg once daily. The maximum daily dose is 1000mg, divided into 2 doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73㎡, respectively, this medicine must be discontinued immediately.

Children's dosage

Children aged 10 years and older or adolescents who are growing: The usual starting dose is 500 milligrams once daily, taken during or after a meal. Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse effects may improve with gradual dose increases. The maximum daily dose is 2000mg. Divide this dose into 2~3 doses.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia; therefore, caution is needed. It should not be administered to patients with moderate to severe renal impairment, dehydration, serious infections, cardiovascular collapse, acute myocardial infarction, sepsis, or other acute conditions. Patients with acute and unstable heart failure should also avoid this medication, and it should be temporarily discontinued before and after tests using iodine-based contrast agents. Patients who have previously had an allergic reaction to this medication or to biguanide drugs, as well as those with type 1 diabetes or acute metabolic acidosis, should not use this medication. Patients with severe infections, severe traumatic systemic disorders, or those scheduled for surgery (especially when food or fluid intake is restricted) should also temporarily discontinue this medication. Patients with poor nutritional status, liver dysfunction, lung dysfunction, or excessive alcohol intake require caution. During treatment with this medication, irregular meals, intense exercise, or the use of interacting medications may pose a risk of lactic acidosis and hypoglycemia, so careful administration is advised. Lactic acidosis is a rare but very serious side effect; if symptoms such as fever, muscle pain, difficulty breathing, weakness, or abdominal pain occur, immediate medical attention should be sought. Gastrointestinal side effects like diarrhea, nausea, and vomiting are common, and symptoms may be alleviated by gradually increasing the dose or taking it with meals initially. Hypoglycemia is rare with monotherapy, but caution is required when taken with other hypoglycemic agents or alcohol. Regular monitoring of renal function is necessary to prevent the accumulation of this medication and to adjust the dose if needed. During pregnancy, since this medication crosses the placenta, it should be avoided if there is a risk of placental insufficiency or preeclampsia, and fetal growth should be closely monitored. During breastfeeding, since this medication is secreted in breast milk, a careful decision should be made whether to continue breastfeeding or to discontinue the medication. Elderly patients often have impaired renal function and should start at the lowest dose while frequently monitoring renal function. Some interactions may occur with this medication and other medications, so patients taking other medications should consult with healthcare professionals. In case of overdose, blood dialysis can remove the drug, so immediate emergency treatment is required if overdose is suspected. This medication helps to control blood sugar without causing weight gain, making it favorable for patients who need weight management. Keep this medication out of the reach of children and ensure it is not transferred to another container.

Side effects

  • Lactic acidosis
  • diarrhea
  • nausea
  • vomiting
  • abdominal distension
  • loss of appetite
  • indigestion
  • constipation
  • abdominal pain
  • metallic taste
Show 7 more
  • rash
  • anemia
  • leukopenia
  • thrombocytopenia
  • vitamin B12 deficiency
  • liver dysfunction
  • severe delayed hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is also recommended to store it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablets

Package unit

500 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.